Cart
sales@molnova.com
BMS-488043
CAS No. 452296-83-2
BMS-488043( —— )
Catalog No. M34526 CAS No. 452296-83-2
BMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 210 | Get Quote |
|
| 5MG | 323 | Get Quote |
|
| 10MG | 485 | Get Quote |
|
| 25MG | 762 | Get Quote |
|
| 50MG | 1058 | Get Quote |
|
| 100MG | 1395 | Get Quote |
|
| 500MG | 2673 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS-488043
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.
-
DescriptionBMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.BMS-488043 is used for the treatment of immune disorders, infections, and genitourinary disorders, and can be used in the study of HIV infect
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number452296-83-2
-
Formula Weight422.43
-
Molecular FormulaC22H22N4O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C(=O)N1CCN(C(=O)C2=CC=CC=C2)CC1)(=O)C=3C=4C(=C(OC)N=CC4OC)NC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
BMS-488043
BMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.
-
Tenofovir alafenamid...
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an orally available precursor of Tenofovir with anti-HIV activity, used to prevent HIV infection.
-
BNM-III-170
BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.
